Corcept Therapeutics Incorporated (NASDAQ:CORT) — Market Cap & Net Worth
Market Cap & Net Worth: Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $3.42 Billion ($3.42 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4564 globally and #1478 in its home market, demonstrating a 14.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Corcept Therapeutics Incorporated's stock price $51.42 by its total outstanding shares 106374020 (106.37 Million). Analyse how efficiently does Corcept Therapeutics Incorporated generate cash to see how efficiently the company converts income to cash.
Corcept Therapeutics Incorporated Market Cap History: 2015 to 2026
Corcept Therapeutics Incorporated's market capitalization history from 2015 to 2026. Data shows growth from $529.74 Million to $5.47 Billion (27.91% CAGR).
Index Memberships
Corcept Therapeutics Incorporated is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Biotechnology
BTK
|
$910.33 Billion | 0.38% | #26 of 30 |
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.14% | #103 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #493 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.54 Trillion | 0.55% | #144 of 602 |
Weight: Corcept Therapeutics Incorporated's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Corcept Therapeutics Incorporated Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Corcept Therapeutics Incorporated's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.86x
Corcept Therapeutics Incorporated's market cap is 4.86 times its annual revenue
Latest Price to Earnings (P/E) Ratio
37.15x
Corcept Therapeutics Incorporated's market cap is 37.15 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $772.28 Million | $81.32 Million | $8.14 Million | 9.50x | 94.87x |
| 2017 | $1.92 Billion | $159.20 Million | $129.12 Million | 12.07x | 14.88x |
| 2018 | $1.42 Billion | $251.25 Million | $75.41 Million | 5.66x | 18.85x |
| 2019 | $1.29 Billion | $306.49 Million | $94.18 Million | 4.20x | 13.67x |
| 2020 | $2.78 Billion | $353.87 Million | $106.01 Million | 7.86x | 26.25x |
| 2021 | $2.11 Billion | $365.98 Million | $112.51 Million | 5.76x | 18.72x |
| 2022 | $2.16 Billion | $401.86 Million | $101.42 Million | 5.38x | 21.30x |
| 2023 | $3.46 Billion | $482.38 Million | $106.14 Million | 7.16x | 32.55x |
| 2024 | $5.36 Billion | $675.04 Million | $139.73 Million | 7.94x | 38.36x |
| 2025 | $3.70 Billion | $761.41 Million | $99.65 Million | 4.86x | 37.15x |
Competitor Companies of CORT by Market Capitalization
Companies near Corcept Therapeutics Incorporated in the global market cap rankings as of May 4, 2026.
Key companies related to Corcept Therapeutics Incorporated by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Corcept Therapeutics Incorporated Historical Marketcap From 2015 to 2026
Between 2015 and today, Corcept Therapeutics Incorporated's market cap moved from $529.74 Million to $ 5.47 Billion, with a yearly change of 27.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.47 Billion | +47.76% |
| 2025 | $3.70 Billion | -30.94% |
| 2024 | $5.36 Billion | +55.14% |
| 2023 | $3.46 Billion | +59.92% |
| 2022 | $2.16 Billion | +2.58% |
| 2021 | $2.11 Billion | -24.31% |
| 2020 | $2.78 Billion | +116.20% |
| 2019 | $1.29 Billion | -9.43% |
| 2018 | $1.42 Billion | -26.02% |
| 2017 | $1.92 Billion | +148.76% |
| 2016 | $772.28 Million | +45.78% |
| 2015 | $529.74 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Corcept Therapeutics Incorporated was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.42 Billion USD |
| MoneyControl | $3.42 Billion USD |
| MarketWatch | $3.42 Billion USD |
| marketcap.company | $3.42 Billion USD |
| Reuters | $3.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more